LONRF2

Across TCGA pan-cancer cohorts, LONRF2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of LONRF2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LONRF2 RNA is repressed in tumor relative to normal tissue. In most cancer types LONRF2 is over-expressed in tumor, although a few such as KIRC and COAD show the opposite, repressed pattern.

KIRC, COAD, and BLCA are the cancer types where LONRF2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LONRF2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	−1.400	<.001	12	view →
COAD	Male	II,III,IV	−1.168	<.001	10	view →
BLCA	Male	IV	−2.932	<.001	9	view →
THCA	All	III,IV	+1.803	<.001	9	view →
UCEC	All	III,IV	−3.241	<.001	8	view →
KIRP	Male	All	−1.286	<.001	7	view →
LUSC	All	II,III,IV	−1.034	<.001	6	view →
STAD	Female	All	−2.204	<.001	5	view →
READ	All	All	−1.902	<.001	5	view →
HNSC	All	All	−0.491	<.001	5	view →
CHOL	All	All	+1.540	<.001	3	view →
LUAD	All	IV	+1.384	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

LONRF2–KIRC

Open the KIRC breakdown →